COMMUNIQUÉS West-GlobeNewswire
-
Avinger Announces Change in Board Leadership
11/12/2017 - 22:15 -
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
11/12/2017 - 22:15 -
Wright Medical Group N.V. to Present at 36th Annual J.P. Morgan Healthcare Conference
11/12/2017 - 22:15 -
argenx announces launch of proposed public offering in the United States
11/12/2017 - 22:11 -
Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation
11/12/2017 - 22:05 -
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments
11/12/2017 - 22:05 -
Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
11/12/2017 - 22:05 -
OrthoPediatrics Corp. Launches New Wrist Fusion Plate System
11/12/2017 - 22:05 -
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting
11/12/2017 - 22:04 -
OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting
11/12/2017 - 22:04 -
Transparency notification
11/12/2017 - 22:02 -
Achaogen Appoints Blake Wise Chief Executive Officer
11/12/2017 - 22:01 -
Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering
11/12/2017 - 22:01 -
Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round
11/12/2017 - 22:01 -
156 Genesis HealthCare Sites Earn National Quality Improvement Recognition
11/12/2017 - 22:01 -
Aduro Biotech to Host a Program Update Call
11/12/2017 - 22:01 -
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
11/12/2017 - 22:01 -
New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML
11/12/2017 - 22:00 -
NAPA’s Jonathan Markley Named to Top Doctor’s list by New Jersey Monthly
11/12/2017 - 20:00
Pages